Recent Updates — ESLA

On October 25, 2026, Estrella Immunopharma appointed Cynthia Pussinen as Chief Executive Officer, Class I director, and Chairperson of the Board. She receives a $250,000 base salary with automatic increases tied to funding milestones and a 1,000,000-share option grant. Cheng Liu ceased serving as CEO, remaining as President and Chief Scientific Officer. The company also proposed eliminating its authority to leave director classes unoccupied, aiming for equal class sizes by 2027. Estrella Immunopharma operates in the biotechnology industry, focusing on immunotherapy treatments.

Estrella Immunopharma, Inc. received a written notification from Nasdaq on August 17, 2026, indicating non-compliance with the $1.00 minimum bid price requirement due to its common stock closing below that threshold for 30 consecutive business days ending August 14, 2026. The company has been granted an initial compliance period of 180 calendar days, expiring on February 16, 2027, during which the closing bid price must reach at least $1.00 for ten consecutive business days to regain listing status. Nasdaq may require a longer compliance period or mandate a reverse stock split completed no later than ten business days before the deadline if chosen as the cure method. Failure to comply by the expiration date could result in further proceedings leading to potential delisting, subject to an appeal process. Estrella Immunopharma operates in the biotechnology industry, focusing on immunopharmaceutical drug development.